DOCSLIB.ORG

ANTIHISTAMINES, FIRST GENERATION; Current Product Listing

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ANTIHISTAMINES, FIRST GENERATION; Current Product Listing ANTIHISTAMINES, FIRST GENERATION; Current Product Listing LABEL NAME MANUFACTURER DRUG TYPE PROVIDER SYNERGIES BRAND NAME ROUTE AHIST 25 MG TABLET MAGNA PHARM SSB AHIST TABLET OTC (ORAL) ALLER-CHLOR 4 MG TABLET RUGBY GEN CHLORPHENIRAMINE TABLET OTC (ORAL) ALLER-G-TIME 25 MG CAPLET TIME-CAP LABS GEN DIPHENHYDRAMINE TABLET OTC (ORAL) ALLERGY 25 MG CAPSULE generic GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) ALLERGY 25 MG TABLET generic GEN DIPHENHYDRAMINE TABLET OTC (ORAL) ALLERGY 4 MG TABLET generic GEN CHLORPHENIRAMINE TABLET OTC (ORAL) ALLERGY 50 MG/20 ML SOLUTION AMERISOURCE-GNP GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) ALLERGY RELIEF 12.5 MG/5 ML LLORENS PHARM GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) ALLERGY RELIEF 25 MG CAPSULE generic GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) ALLERGY RELIEF 25 MG SOFTGEL generic GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) ALLERGY RELIEF 25 MG TABLET generic GEN DIPHENHYDRAMINE TABLET OTC (ORAL) ALLERGY RELIEF 4 MG TABLET LEADER GEN CHLORPHENIRAMINE TABLET OTC (ORAL) ALLERGY-TIME 4 MG TABLET TIME-CAP LABS GEN CHLORPHENIRAMINE TABLET OTC (ORAL) BANOPHEN 25 MG CAPSULE MAJOR PHARMACEU GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) BANOPHEN 25 MG TABLET MAJOR PHARMACEU GEN DIPHENHYDRAMINE TABLET OTC (ORAL) BANOPHEN 50 MG CAPSULE MAJOR PHARMACEU GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) CARBINOXAMINE 4 MG/5 ML LIQUID BRECKENRIDGE GEN CARBINOXAMINE LIQUID (ORAL) CARBINOXAMINE MALEATE 4 MG TAB generic GEN CARBINOXAMINE TABLET (ORAL) CHILD ALLERGY RLF 12.5 MG/5 ML LEADER GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) CHILD DIPHENHYDRAMIN 12.5 MG/5 PRECISION DOSE GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) CHILD DIPHENHYDRAMIN 25MG/10ML PRECISION DOSE GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) CHILD'S ALLERGY 12.5 MG/5 ML generic GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) CHLD ALLRGY RLF 12.5MG CHEW TB AMERISOURCE-GNP GEN DIPHENHYDRAMINE CHEW OTC (ORAL) CLEMASTINE FUM 2.68 MG TAB TEVA USA GEN CLEMASTINE TABLET (ORAL) CYPROHEPTADINE 2 MG/5 ML SOLN generic GEN CYPROHEPTADINE SYRUP (ORAL) CYPROHEPTADINE 2 MG/5 ML SYRUP generic GEN CYPROHEPTADINE SYRUP (ORAL) CYPROHEPTADINE 4 MG TABLET generic GEN CYPROHEPTADINE TABLET (ORAL) CYPROHEPTADINE 4 MG/10 ML SYRP PHARMACEUTICAL GEN CYPROHEPTADINE SYRUP (ORAL) DAYHIST ALLERGY 1.34 MG TABLET TOPCO GEN CLEMASTINE TABLET OTC (ORAL) DIPHEDRYL 12.5 MG/5 ML ELIXIR AMERISOURCE-GNP GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) DIPHEDRYL ALLERGY CAPSULE AMERISOURCE-GNP GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) DIPHENHIST 25 MG CAPSULE RUGBY GEN DIPHENHYDRAMINE TABLET OTC (ORAL) DIPHENHYDRAMINE 12.5 MG/5 ML generic GEN DIPHENHYDRAMINE ELIXIR (ORAL) DIPHENHYDRAMINE 25 MG CAPSULE generic GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) DIPHENHYDRAMINE 25 MG TABLET generic GEN DIPHENHYDRAMINE TABLET OTC (ORAL) DIPHENHYDRAMINE 25 MG/10 ML generic GEN DIPHENHYDRAMINE ELIXIR (ORAL) DIPHENHYDRAMINE 50 MG CAPSULE generic GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) DIPHENHYDRAMINE 6.25 MG/ML DRP WESTMINSTER PHA GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) GS ALLERGY RELIEF 25 MG CAP PERRIGO/GOODSEN GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) GS ALLERGY RELIEF 25 MG TABLET PERRIGO/GOODSEN GEN DIPHENHYDRAMINE TABLET OTC (ORAL) GS ALLERGY RELIEF 4 MG TABLET PERRIGO/GOODSEN GEN CHLORPHENIRAMINE TABLET OTC (ORAL) GS CHILD ALLERGY 12.5 MG/5 ML PERRIGO/GOODSEN GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) HISTEX 1.25 MG CHEWABLE TABLET ALLEGIS PHARMAC SSB HISTEX CHEW OTC (ORAL) HISTEX 2.5 MG/5 ML SYRUP ALLEGIS PHARMAC SSB HISTEX LIQUID OTC (ORAL) HISTEX PD 0.938 MG/ML DROP ALLEGIS PHARMAC SSB HISTEX PD DROPS OTC (ORAL) HISTEX PDX 1.25 MG/ML DROP ALLEGIS PHARMAC SSB HISTEX PDX DROPS OTC (ORAL) HM ALLERGY 25 MG TABLET HEALTH MART GEN DIPHENHYDRAMINE TABLET OTC (ORAL) HM ALLERGY RELIEF 25 MG CAP HEALTH MART GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) HM ALLERGY RELIEF 25 MG TABLET HEALTH MART GEN DIPHENHYDRAMINE TABLET OTC (ORAL) HM ALLERGY RELIEF 4 MG TABLET HEALTH MART GEN CHLORPHENIRAMINE TABLET OTC (ORAL) HM CHILD ALLERGY 12.5 MG/5 ML HEALTH MART GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) HYDROXYZINE 10 MG/5 ML SOLN MORTON GROVE PH GEN HYDROXYZINE SOLUTION (ORAL) HYDROXYZINE 10 MG/5 ML SYRUP SILARX/LANNETT GEN HYDROXYZINE SOLUTION (ORAL) HYDROXYZINE HCL 10 MG TABLET generic GEN HYDROXYZINE TABLET (ORAL) HYDROXYZINE HCL 25 MG TABLET generic GEN HYDROXYZINE TABLET (ORAL) HYDROXYZINE HCL 50 MG TABLET generic GEN HYDROXYZINE TABLET (ORAL) HYDROXYZINE PAM 100 MG CAP TEVA USA GEN HYDROXYZINE CAPSULE (ORAL) HYDROXYZINE PAM 25 MG CAP generic GEN HYDROXYZINE CAPSULE (ORAL) HYDROXYZINE PAM 50 MG CAP generic GEN HYDROXYZINE CAPSULE (AG) (ORAL) KARBINAL ER 4 MG/5 ML SUSP ZYLERA/CERECOR SSB KARBINAL ER SUSPENSION (ORAL) M-HIST PD 0.625 MG/ML DROP METHOD PHARMACE GEN M-HIST PD DROPS OTC (ORAL) MICLARA LQ 1.25 MG/5 ML SYRUP KEY THERAPEUTIC SSB MICLARA LQ OTC (ORAL) PEDIACLEAR ALLERGY 0.313 MG/ML G.M. PHARM SSB PEDIACLEAR ALLERGY DROPS OTC (ORAL) PEDIACLEAR COUGH 6.25 MG/ML G.M. PHARM SSB PEDIACLEAR COUGH DROPS OTC (ORAL) PEDIACLEAR PD 0.625 MG/ML DROP G.M. PHARM SSB PEDIACLEAR PD DROPS OTC (ORAL) PEDIACLEAR-8 12.5 MG/15 ML LIQ G.M. PHARM SSB PEDIACLEAR-8 LIQUID OTC (ORAL) PEDIAVENT 1 MG TABLET CHEW CARWIN ASSOCIAT SSB PEDIAVENT TAB CHEW OTC (ORAL) 1 ANTIHISTAMINES, FIRST GENERATION; Current Product Listing LABEL NAME MANUFACTURER DRUG TYPE PROVIDER SYNERGIES BRAND NAME ROUTE PEDIAVENT 2 MG/5 ML SYRUP CARWIN ASSOCIAT SSB PEDIAVENT LIQUID OTC (ORAL) PHARBECHLOR 4 MG TABLET PHARBEST PHARMA GEN CHLORPHENIRAMINE TABLET OTC (ORAL) PHARBEDRYL 25 MG CAPSULE PHARBEST PHARMA GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) PHARBEDRYL 50 MG CAPSULE PHARBEST PHARMA GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) QC CHILD ALLERGY 12.5 MG/5 ML CHAIN DRUG GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) QC COMPLETE ALLERGY 25 MG CAP CHAIN DRUG GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) RYCLORA 2 MG/5 ML SOLUTION CARWIN ASSOCIAT SSB RYCLORA (ORAL) RYVENT 6 MG TABLET CARWIN ASSOCIAT SSB RYVENT TABLET (ORAL) SILADRYL 12.5 MG/5 ML LIQUID SILARX/LANNETT GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) SILADRYL 25 MG/10 ML LIQUID AHP GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) SM ALLERGY 4 MG TABLET SUNMARK GEN CHLORPHENIRAMINE TABLET OTC (ORAL) SM ALLERGY 4-HR 4 MG TABLET SUNMARK GEN CHLORPHENIRAMINE TABLET OTC (ORAL) SM ALLERGY RELIEF 12.5 MG/5 ML SUNMARK GEN DIPHENHYDRAMINE LIQUID OTC (ORAL) SM ALLERGY RELIEF 25 MG CAP SUNMARK GEN DIPHENHYDRAMINE CAPSULE OTC (ORAL) SM ALLERGY RELIEF 25 MG TABLET SUNMARK GEN DIPHENHYDRAMINE TABLET OTC (ORAL) SM ALLERGY RELIEF 4 MG TABLET SUNMARK GEN CHLORPHENIRAMINE TABLET OTC (ORAL) TRIPROLIDINE 0.313 MG/ML DROP WESTMINSTER PHA GEN TRIPROLIDINE OTC (ORAL) TRIPROLIDINE 0.625 MG/ML DROP generic GEN TRIPROLIDINE OTC (ORAL) TRIPROLIDINE 0.938 MG/ML DROPS generic GEN TRIPROLIDINE DROPS OTC (ORAL) TRIPROLIDINE 2.5 MG/5 ML LIQ RUGBY GEN TRIPROLIDINE DROPS OTC (ORAL) VANACLEAR PD 0.313 MG/ML DROP G.M. PHARM SSB VANACLEAR PD DROPS OTC (ORAL) VANAMINE PD 6.25 MG/ML DROPS G.M. PHARM SSB VANAMINE PD DROPS OTC (ORAL) 2.
Load more

Recommended publications
  • For Personal Use Only
    SedatiWITH ANTIi ® Dowden Health Media CopyrightFor personal use only Initiate the antipsychotic at a reasonable, not overly high dose, then use a nonantipsychotic to help control insomnia, anxiety, and agitation For mass reproduction, content licensing and permissions contact Dowden Health Media. pSYCHIATRY i PSYCHOTICSon edation is a frequent side effect of antipsychot- ics, especially at relatively high doses. Antipsy- S chotics’ sedative effects can reduce agitation in acute psychosis and promote sleep in insomnia, but Manage, don’t long-term sedation may: • interfere with schizophrenia patients’ efforts to go accept adverse to work or school or engage in normal socialization • prevent improvement from psychosocial training, psychiatric rehabilitation, and other treatments. ‘calming’ eff ect This article discusses how to manage acute psycho- sis without oversedation and ways to address persistent sedation and chronic insomnia with less-sedating anti- Del D. Miller, PharmD, MD Professor of psychiatry psychotics or adjunctive medications. University of Iowa Carver College of Medicine Iowa City Neurobiology or psychopharmacology? Many patients experience only mild, transient som- nolence at the beginning of antipsychotic treatment, and most develop some tolerance to the sedating ef- fects with continued administration. Others may have persistent daytime sedation that interferes with nor- mal functioning. Sedation is especially common in elderly patients re- ceiving antipsychotics. Compared with younger patients, older patients receiving
    [Show full text]
  • The Case of Ketamine Allergy
    CASE REPORT The Case of Ketamine Allergy William Bylund, MD Department of Emergency Medicine, Naval Medical Center Portsmouth, Portsmouth, Virginia Liam Delahanty, MD Maxwell Cooper, MD Section Editor: Rick A. McPheeters, DO Submission history: Submitted April 3, 2017; Revision received June 29, 2017; Accepted July 11, 2017 Electronically published October 3, 2017 Full text available through open access at http://escholarship.org/uc/uciem_cpcem DOI: 10.5811/cpcem.2017.7.34405 Ketamine is often used for pediatric procedural sedation due to low rates of complications, with allergic reactions being rare. Immediately following intramuscular (IM) ketamine administration, a three-year-old female rapidly developed facial edema and diffuse urticarial rash, with associated wheezing and oxygen desaturation. Symptoms resolved following treatment with epinephrine, dexamethasone and diphenhydramine. This case presents a clinical reaction to ketamine consistent with anaphylaxis due to histamine release, but it is uncertain whether this was immunoglobulin E mediated. This is the only case reported to date of allergic reaction to IM ketamine, without co- administration of other agents. [Clin Pract Cases Emerg Med.2017;1(4):323–325.] INTRODUCTION cardiac monitor, end tidal CO2 (ETCO2) and pulse oximetry Ketamine is a common medication, used in isolation as well (POx), in addition to being placed on two liters nasal cannula as with other agents, for pediatric sedation in the emergency (NC). No intravenous (IV) access was obtained prior to sedation. department (ED). It is often turned to because of its efficacy, ease Seventy milligrams (4.4mg/kg) of ketamine was administered IM of use, and favorable safety profile. Common side effects of into the right thigh.
    [Show full text]
  • Diphenhydramine Dosage Sheet Concord Pediatrics, P.A
    Diphenhydramine Dosage Sheet Concord Pediatrics, P.A. (603) 224-1929 BRAND NAMES: Benadryl INDICATIONS: Treatment of allergic reactions, nasal allergies, hives and itching. FREQUENCY: Repeat every 6 hours as needed. Don't give more than 4 times a day. DOSAGE: Determine by using the table below. Please speak with a medical provider before giving Diphenhydramine to a child under 1 year old. Child’s Dose in mg Children’s Liquid Chewable/Fastmelts Tabs/Caps/Gels Weight (lb) (12.5mg/ 5mL) 12.5mg tablets 25mg tablets *12-16 lbs 6.25 mg 2.5 mL *17-19 lbs 9.375 mg 3.75 mL *20-24 lbs 10 mg 4 mL 25-37 lbs 12.5 mg 5 mL 1 tab 38-49 lbs 18.75 mg 7.5 mL 1.5 tabs 50-69 lbs 25 mg 10 mL 2 tabs 1 tab 70-99 lbs 37.5 mg 15 mL 3 tabs 1.5 tabs >100 lbs 50 mg 20 mL 4 tabs 2 tabs Table Notes: *AGE LIMIT: For allergies, don't use under 1 year of age (Reason: it's a sedative). For colds, not recommended at any age (Reason: no proven benefits) and should be avoided if under 4 years old. Avoid multi-ingredient products in children under 6 years of age (Reason: FDA recommendations 10/2008). MEASURING the DOSAGE: Syringes and droppers are more accurate than teaspoons. If possible, use the syringe or dropper that comes with the medicine. If not, medicine syringes are available at pharmacies. Regular spoons are not reliable. ADULT DOSAGE: 50 mg Why use Diphenhydramine? Antihistamines can be used to treat your child’s runny nose, itchy eyes, and sneezing due to allergies.
    [Show full text]
  • Chronic Pain Management Toolkit
    Chronic Pain Management Urine Drug Testing Toolkit Screening (see chart on next page) Most guidelines recommend screening patients to determine risks of drug misuse and abuse and to mitigate those risks as much as possible. Unfortunately, there are no risk assessment tools that have been validated in multiple settings and populations. Screening is typically based on risk factors that can be identified through a thorough patient history, the use of prescription drug monitoring programs (PDMPs), the opioid risk tool (provided in this toolkit), and, on occasion, drug screening. However, it is important to standardize testing as cited risk factors (e.g. sociodemographic factors, psychological comorbidity, substance use disorders, etc.) might unfairly impact certain vulnerable populations. Involvement of the whole health care team and full disclosure and discussion of the screening protocol with patients is central to providing patient-centered and comprehensive pain management. Prior to drug testing, physicians should inform the patient of the reason(s) for testing, how often they will be tested, and what the results might mean. This gives patients an opportunity to disclose any additional drug or substance use which may help with identification of false positives and appropriate interpretation of test results. Physicians must understand the limitations of the urine and confirmatory tests available, including what substances are detected by a particular test, and the reasons for false-positive and false-negative tests. Changes in prescribing for a particular patient should not be based on the result of one abnormal screening test, but should only occur after looking at all available monitoring tools as well as repeating the drug screen with the most specific test available.
    [Show full text]
  • Children with Respiratory Disorders: Asthma and Allergies
    Oral Health Fact Sheet for Dental Professionals Children with Respiratory Disorders: Asthma and Allergies Asthma is a chronic respiratory disease associated with airway obstruction, with recurrent attacks of paroxysmal dyspnea, and wheezing due to spasmodic contraction of the bronchi. (ICD 9 code 493.2) Allergy is a hypersensitivity to an agent caused by an immunologic response to an initial exposure. (ICD 9 code 995.3) Prevalence • Asthma affects 9.3% of the population, higher in females and African-Americans Manifestations Clinical • Constriction of bronchi, coughing, wheezing, chest tightness, and shortness of breath Oral • Increased caries risk, enamel defects • Increased gingivitis and periodontal disease risk; and more calculus • Higher rates of malocclusion and increased: overjet, overbite, posterior crossbite; high palatal vault • Oral candidiasis, xerostomia, decreased salivary flow rate and salivary pH Other Potential Disorders/Concerns • none Management Medication SYMPTOM MEDICATION SIDE EFFECTS Breathing difficulties A. Bronchodilators (Β2-agonists) A. Oral candidiasis, xerostomia, decreased salivary flow rate B. Corticosteroids B. Oral candidiasis, dental caries C. Antihistamines C. Xerostomia D. Decongestants D. Xerostomia Sedation • Hydroxyzine and benzodiazepines recommended; avoid narcotics and barbiturates due to their histamine releasing properties → bronchospasm and potentiated allergic response. Intravenous sedation • Use extreme caution due to limited control of the airway. Avoid • Aspirin, other salicylates and NSAIDS (due to allergies) may provoke a severe exacerbation of bronchoconstriction; use acetaminophen. Behavioral Stress-management techniques; may use nitrous oxide in mild to moderate asthmatics after medical consultation. Anxiety can cause acute exacerbation. Children with Respiratory Disorders: Asthma and Allergies continued Dental Treatment and Prevention • Assess child’s risk of acute exacerbation/anaphylaxis during dental treatment prior to examination.
    [Show full text]
  • Ketamine and Serotonin Syndrome: a Case Report
    Residents’ Voices Ketamine and serotonin syndrome: A case report Clay Gueits, MD, and Martin Witkin, DO ong utilized as a rapid anesthetic, ket- with haloperidol (dose unknown) with amine has been increasingly used in reportedly good effect. On Day 7, she was Lsub-anesthetic doses for several psy- discharged home. chiatric indications, including depression, Upon returning home, she experienced suicidality, and chronic pain. Recently, persistent altered mental status. Her signifi- an intranasal form of esketamine—the cant other brought her to our hospital for fur- S-enantiomer of ketamine—was FDA- ther workup. Ms. O’s body temperature was Clay Gueits, MD approved for treatment-resistant depression. 37.6°C, and she was diaphoretic. Her blood Previously, researchers believed ketamine pressure was 154/100 mm Hg, and her heart mediated its analgesic and psychotropic rate was 125 bpm. On physical examination, effects solely via N-methyl-d-aspartate she had 4+ patellar and Achilles reflexes (NMDA) receptor antagonism, but emerg- with left ankle clonus and crossed adductors. ing research has described a seemingly more Her mental status exam showed increased complex receptor profile.1 One such ancillary latency of thought and speech, with bizarre pharmacologic mechanism is occupation of affect as evidenced by illogical mannerisms Martin Witkin, DO the serotonin receptor.1,2 However, there and appearance. She said she was “not feel- is sparse literature describing the possible ing myself” and would stare at walls for pro- Dr. Gueits is a PGY-2 Psychiatry extent of ketamine’s involvement in sero- longed periods of time, appearing internally Resident, Department of Psychiatry, tonin syndrome.3 Here, we describe a case preoccupied and confused.
    [Show full text]
  • Diphenhydramine (Systemic) Epinephrine (Systemic)
    DIPHENHYDRAMINE (SYSTEMIC) ^ Diphenhist [OTC] see DiphenhydrAMINE (Systemic) on page 34 Insomnia, occasional: Oral: Children 2 to 12 years, weighing 10 to 50 kg (off-label use): DiphenhydrAMINE (Systemic) Limited data available: 1 mg/kg administered 30 minutes before bedtime; maximum single dose: 50 mg (Russo, 1976) Brand Names: US Aler-Dryl [OTC]; Allergy Relief Childrens Children ≥12 years and Adolescents: Refer to adult dosing. [OTC]; Allergy Relief [OTC]; Altaryl [OTC]; Anti-Hist Allergy [OTC]; Motion sickness: Banophen [OTC]; Benadryl Allergy Childrens [OTC]; Benadryl Prophylaxis: Oral: Allergy [OTC]; Benadryl Dye-Free Allergy [OTC]; Benadryl [OTC]; Manufacturer's labeling: Infants, Children, and Adolescents: Complete Allergy Medication [OTC]; Complete Allergy Relief [OTC]; Note: Administer 30 minutes before motion Dicopanol FusePaq; Dicopanol RapidPaq; Diphen [OTC]; Diphenh- Weight-directed dosing: 5 mg/kg/day divided into 3 to 4 doses; ist [OTC]; Genahist [OTC]; Geri-Dryl [OTC]; GoodSense Allergy maximum: 300 mg daily Relief [OTC]; Naramin [OTC]; Nighttime Sleep Aid [OTC]; Nytol Fixed dosing: 12.5 to 25 mg 3 to 4 times daily Maximum Strength [OTC]; Nytol [OTC]; Ormir [OTC]; PediaCare Alternate dosing: Children 2 to 12 years: Limited data available: Childrens Allergy [OTC]; Pharbedryl; Pharbedryl [OTC]; Q-Dryl 0.5 to 1 mg/kg/dose every 6 hours; maximum single dose: [OTC]; QlearQuil Nighttime Allergy [OTC]; Quenalin [OTC] [DSC]; 25 mg. First dose should be administered 1 hour before travel Scot-Tussin Allergy Relief [OTC]; Siladryl
    [Show full text]
  • Reduced Levels of Serotonin 2A Receptors Underlie Resistance of Egr3-Deficient Mice to Locomotor Suppression by Clozapine
    Neuropsychopharmacology (2012) 37, 2285–2298 & 2012 American College of Neuropsychopharmacology. All rights reserved 0893-133X/12 www.neuropsychopharmacology.org Reduced Levels of Serotonin 2A Receptors Underlie Resistance of Egr3-Deficient Mice to Locomotor Suppression by Clozapine 1 2 3 4 4 4 Alison A Williams , Wendy M Ingram , Sarah Levine , Jack Resnik , Christy M Kamel , James R Lish , 4 3 4 5 5,6 Diana I Elizalde , Scott A Janowski , Joseph Shoker , Alexey Kozlenkov , Javier Gonza´lez-Maeso and ,4 Amelia L Gallitano* 1 2 School of Life Sciences, Arizona State University, Tempe, AZ, USA; Department of Molecular and Cell Biology, Life Sciences Addition, 3 4 University of California, Berkeley, CA, USA; University of Arizona College of MedicineFTucson, Tucson, AZ, USA; Department of Basic Medical 5 Sciences and Psychiatry, University of Arizona College of MedicineFPhoenix, Phoenix, AZ, USA; Department of Psychiatry, Mount Sinai 6 School of Medicine, New York, NY, USA; Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA The immediate-early gene early growth response 3 (Egr3) is associated with schizophrenia and expressed at reduced levels in postmortem patients’ brains. We have previously reported that Egr3-deficient (Egr3À/À) mice display reduced sensitivity to the sedating effects of clozapine compared with wild-type (WT) littermates, paralleling the heightened tolerance of schizophrenia patients to antipsychotic side effects. In this study, we have used a pharmacological dissection approach to identify a neurotransmitter receptor defect in Egr3À/À mice that may mediate their resistance to the locomotor suppressive effects of clozapine. We report that this response is specific to second- / generation antipsychotic agents (SGAs), as first-generation medications suppress the locomotor activity of Egr3À À and WT mice to a similar degree.
    [Show full text]
  • A Strategy to Decrease the Use of Risky Drugs in the Elderly
    REVIEW SUSAN M. FOSNIGHT, RPH, CGP, BCPS KYLE R. ALLEN, DO CME Clinical Staff Pharmacist, Department of Pharmacy, Summa Health Chief, Division of Geriatric Medicine, Medical Director, Post Acute CREDIT System, Akron, OH and Senior Services, Summa Health System; Associate Professor of Clinical Internal and Family Medicine, Northeastern Ohio Universities College of Medicine, Akron, OH CAROLYN M. HOLDER, MSN, RN, CNS SUSAN HAZELETT, MSN, RN Geriatrics Coordinator, Post Acute and Senior Services, Summa Research Associate, Summa Health System, Akron, OH Health System, Akron, OH A strategy to decrease the use of risky drugs in the elderly ■ ABSTRACT OME MEDICATIONS that are safe in most S patients are best avoided in elderly Many medications that are safe in most patients pose patients—and pharmacists can help physicians serious risks in older patients, including functional avoid them. decline, delirium, falls, and poorer outcomes. We describe In this paper we discuss three medications, our institution’s program of “academic detailing,” chosen on the basis of scientific evidence and designed to reduce the use of three high-risk drugs in our personal experience, that are associated elderly patients. with unacceptable risk in elderly patients and for which reasonable alternatives exist: ■ KEY POINTS meperidine, diphenhydramine, and amitripty- line. Meperidine, diphenhydramine, and amitriptyline all pose We also describe our institution’s program a high risk of adverse reactions in older adults. Safer of “academic detailing” to reduce their use. alternatives are available. Whenever a physician prescribes one of these high-risk drugs to an elderly patient at our In our program, the pharmacy computer system generates institution, a computer alerts the pharmacist, a daily report of elderly patients who are prescribed any who contacts the prescribing physician to explain the problems patients often have with of these three agents.
    [Show full text]
  • Nitrous Oxide: Pharmacology, Signs/Symptoms, Patient Selection
    Nitrous Oxide: Pharmacology, Signs/Symptoms, Patient Selection Characteristics of Oxygen Characteristics of Nitrous Oxide Clear Clear Colorless Colorless Tasteless Tasteless (to most) Odorless Odorless Produced by careful heating of ammonium Produced by fractional distillation of air nitrate, which decomposes into nitrous oxide and water vapor. An interesting Note: Another use for nitrous oxide has been as a boost for racecars. 2N2O → 2N2 + O2 As the reaction takes place in the combustion chamber of a car, 33% more gas is produced. This provides a boost to the piston and an increase in heat. Other effects: the oxygen given off accounts for more efficient combustion of fuel, the nitrogen buffers the increased cylinder pressure controlling combustion, and the latent heat of vaporization of the nitrous oxide reduces the intake pressure. The result is a dramatic increase in power and acceleration. Other Notes or Questions to Ask: http://bestdentalCE.com Sunday July 28, 2019 Page 1 of 46 Description of Nitrous Oxide Therapeutic Category - Sedative, Anxiolytic Uses - To induce sedation and analgesia in the anxious dental patient, a principal adjunct to inhalation and IV general anesthesia (GA) in medical patients Route of Administration – Inhalation Dosage - 20 - 70% administered via nasal hood Drug Uptake - N20 is rapidly absorbed via the lungs, onset 1-2 minutes Nitrous oxide is stable and inert at room temperature -- inherent Inherent Molecular Stability molecular stability Physical Constants of N2O • Density of Nitrous oxide = 1.997 g/L • Density of Air = 1.239 g/L Molecular Weight 44.013 Because nitrous oxide is more dense than Boiling Point @ 1 atm (°F) -129.1 air, the greatest concentration of unscavenged gas will be low and near the Freezing Point @ 1 atm (°F) -131.5 floor.
    [Show full text]
  • Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: an American Academy of Sleep Medicine Clinical Practice Guideline Michael J
    pii: jc-00382-16 http://dx.doi.org/10.5664/jcsm.6470 SPECIAL ARTICLES Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline Michael J. Sateia, MD1; Daniel J. Buysse, MD2; Andrew D. Krystal, MD, MS3; David N. Neubauer, MD4; Jonathan L. Heald, MA5 1Geisel School of Medicine at Dartmouth, Hanover, NH; 2University of Pittsburgh School of Medicine, Pittsburgh, PA; 3University of California, San Francisco, San Francisco, CA; 4Johns Hopkins University School of Medicine, Baltimore, MD; 5American Academy of Sleep Medicine, Darien, IL Introduction: The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of chronic insomnia in adults. Methods: The American Academy of Sleep Medicine commissioned a task force of four experts in sleep medicine. A systematic review was conducted to identify randomized controlled trials, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence. The task force developed recommendations and assigned strengths based on the quality of evidence, the balance of benefits and harms, and patient values and preferences.
    [Show full text]
  • Typical and Atypical Antipsychotic Drugs Increase Extracellular Histamine Levels in the Rat Medial Prefrontal Cortex: Contribution of Histamine H1 Receptor Blockade
    ORIGINAL RESEARCH ARTICLE published: 17 May 2012 PSYCHIATRY doi: 10.3389/fpsyt.2012.00049 Typical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial prefrontal cortex: contribution of histamine H1 receptor blockade Matthew J. Fell 1†, Jason S. Katner 1, Kurt Rasmussen1, Alexander Nikolayev 2, Ming-Shang Kuo2, David L. G. Nelson1, Kenneth W. Perry 1 and Kjell A. Svensson1* 1 Psychiatric Disorders, Neuroscience Discovery Research, Eli Lilly and Company, Indianapolis, IN, USA 2 Translational Science, Eli Lilly and Company, Indianapolis, IN, USA Edited by: Atypical antipsychotics such as clozapine and olanzapine have been shown to enhance Bernat Kocsis, Harvard Medical histamine turnover and this effect has been hypothesized to contribute to their improved School, USA therapeutic profile compared to typical antipsychotics. In the present study, we examined Reviewed by: Francesc Artigas, Instituto de the effects of antipsychotic drugs on histamine (HA) efflux in the mPFC of the rat by means Investigaciones Biomédicas de of in vivo microdialysis and sought to differentiate the receptor mechanisms which under- Barcelona, Spain lie such effects. Olanzapine and clozapine increased mPFC HA efflux in a dose related Ritchie Brown, Harvard Medical manner. Increased HA efflux was also observed after quetiapine, chlorpromazine, and per- School, USA phenazine treatment. We found no effect of the selective 5-HT2A antagonist MDL100907, *Correspondence: Kjell A. Svensson, Neuroscience 5-HT2c antagonist SB242084, or the 5-HT6 antagonist Ro 04-6790 on mPFC HA efflux. Discovery Research, Lilly Research HA efflux was increased following treatment with selective H1 receptor antagonists pyril- Laboratories, Lilly Corporate Center, amine, diphenhydramine, and triprolidine, the H3 receptor antagonist ciproxifan and the Indianapolis, IN 46285, USA.
    [Show full text]